Glutamate [NMDA] receptor · PROTEIN COMPLEX GROUP · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Glutamate [NMDA] receptor shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q05586. Start with major depressive disorder, then reuse UniProt Q05586 as the stable protein anchor across project notes and exports.
Start with major depressive disorder, then reuse UniProt Q05586 as the stable protein anchor across project notes and exports.
Glutamate [NMDA] receptor shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.
Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include APIMOSTINEL, AV-101, ESKETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGlutamate receptor ionotropic, NMDA 1
Review this target as Glutamate [NMDA] receptor, mapped to UniProt Q05586. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutamate [NMDA] receptor as ChEMBL target CHEMBL2094124, mapped to UniProt Q05586. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Glutamate [NMDA] receptor is the right protein anchor across sources, using UniProt Q05586 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why major depressive disorder is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Glutamate [NMDA] receptor |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Homo sapiens |
| UniProt | Q05586 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Glutamate receptor ionotropic, NMDA 1 |
| UniProt Accession | Q05586 |
| Component Type | Protein |
| Sequence Length | 938 aa |
Glutamate receptor ionotropic, NMDA 1
Review this target as Glutamate [NMDA] receptor, mapped to UniProt Q05586. ChEMBL maps the protein component as Glutamate receptor ionotropic, NMDA 1. Sequence length is 938 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Glutamate [NMDA] receptor shows approved-linked disease relevance led by major depressive disorder. 5 more disease programs remain visible in the same review block.
Start review with major depressive disorder because it currently carries approved-linked support. Linked drugs include APIMOSTINEL, AV-101, ESKETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL276708 | 9.3 | IC50 | 0.5 | Preclinical |
| CHEMBL12513 | 9.1 | IC50 | 0.8 | Preclinical |
| CHEMBL39881 | 9.02 | Ki | 0.96 | Preclinical |
| CHEMBL12804 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL12242 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL284237 | 8.92 | Ki | 1.2 | Clinical |
| CHEMBL5185347 | 8.85 | Ki | 1.4 | Preclinical |
| CHEMBL273662 | 8.82 | IC50 | 1.5 | Preclinical |
| CHEMBL274422 | 8.82 | IC50 | 1.5 | Preclinical |
| CHEMBL537478 | 8.82 | IC50 | 1.5 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 115 | 317 | 6.4 |
| assay format | 29 | 100 | 5.6 |
| cell membrane format | 9 | 47 | 5.5 |
| cell-based format | 8 | 2 | 6.3 |
| tissue-based format | 2 | 1 | 6.8 |
| cell-free format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 7 | 5 | 6.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 4 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |